-+ 0.00%
-+ 0.00%
-+ 0.00%
Spectral Medical says FDA 100-day PMA review for Toraymyxin does not require new clinical trial
Share
Listen to the news
Spectral Medical says FDA 100-day PMA review for Toraymyxin does not require new clinical trial
  • Spectral Medical received an FDA deficiency letter during the 100-day PMA review for Toraymyxin.
  • FDA flagged additional analyses, testing, and clarifications needed to complete the review.
  • No additional clinical trial was requested as part of the FDA’s 100-day review.
  • Management does not expect the added work to materially change its overall regulatory timeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spectral Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609110700PRIMZONEFULLFEED9824964) on September 11, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending